CNS Pharmaceuticals (NASDAQ:CNSP) issued its earnings results on Friday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03), Fidelity Earnings reports.
Shares of CNSP traded up $0.08 during mid-day trading on Friday, reaching $1.79. The company had a trading volume of 148,767 shares, compared to its average volume of 1,216,502. CNS Pharmaceuticals has a twelve month low of $1.59 and a twelve month high of $4.46. The company’s 50-day moving average is $2.10 and its 200-day moving average is $2.29. The company has a market capitalization of $45.39 million, a P/E ratio of -6.39 and a beta of 2.47.
A number of brokerages have recently issued reports on CNSP. Zacks Investment Research cut CNS Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 17th. Brookline Capital Management began coverage on CNS Pharmaceuticals in a report on Tuesday, February 2nd. They issued a “buy” rating and a $10.00 target price for the company.
CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.
Recommended Story: What impact do institutional investors have on markets?
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.